Early detection of influenza A and B infection in infants and children using conventional and fluorescence-based rapid testing

Rath, Barbara; Tief, Franziska; Obermeier, Patrick; Tuerk, Ewelina; Karsch, Katharina; Muehlhans, Susann; Adamou, Eleni; Duwe, Susanne; Schweiger, Brunhilde

doi:10.1016/j.jcv.2012.08.002

Cited by 38 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From October 1, 2011 to April 30, 2013, all patients fulfilling pre-defined criteria for influenza-like illness (fever ≥38°C and ≥ one respiratory sign or symptom) were assessed consecutively by a specifically trained QM team [7], [21]. Cases were included if i) the patient was 0–18 years of age, and ii) influenza infection was confirmed by RT-PCR in the national reference laboratory.…”

Section: Methodsmentioning

confidence: 99%

“…Second-generation RIDT (such as the SOFIA) use fluorescence-labelled antigens combined with POC readers, providing the advantage of standardized readouts. Evaluations in the US, Asia and Germany revealed improved sensitivities of up to 88% compared to RT-PCR with specificities close to 100% [21]–[24]. Rapid antigen tests reflect the actual amount of viral particles in a given sample, and tend to correlate well with viral culture results [22], [25].…”

Section: Introductionmentioning

confidence: 98%

“…RIDT has been developed for the immediate diagnosis of influenza infections in the acute care setting [16]–[20]. RIDT are most sensitive with CT values <30 [21]. Second-generation RIDT (such as the SOFIA) use fluorescence-labelled antigens combined with POC readers, providing the advantage of standardized readouts.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care

Chen

Yousef²,

Duwe

et al. 2014

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundInfluenza infections induce considerable disease burden in young children. Biomarkers for the monitoring of disease activity at the point-of-care (POC) are currently lacking. Recent methodologies for fluorescence-based rapid testing have been developed to provide improved sensitivities with the initial diagnosis. The present study aims to explore the utility of second-generation rapid testing during longitudinal follow-up of influenza patients (Rapid Influenza Follow-up Testing = RIFT). Signal/control fluorescent readouts (Quantitative Influenza Follow-up Testing = QIFT) are evaluated as a potential biomarker for the monitoring of disease activity at the POC.Methods and FindingsRIFT (SOFIA) and QIFT were performed at the POC and compared to blinded RT-PCR at the National Reference Centre for Influenza. From 10/2011-4/2013, a total of 2048 paediatric cases were studied prospectively; 273 cases were PCR-confirmed for influenza. During follow-up, RIFT results turned negative either prior to PCR (68%), or simultaneously (30%). The first negative RIFT occurred after a median of 8 days with a median virus load (VL) of 5.6×10∧3 copies/ml and cycle threshold of 37, with no evidence of viral rebound. Binning analysis revealed that QIFT differentiated accurately between patients with low, medium and high viral titres. QIFT increase/decrease showed 88% agreement (sensitivity = 52%, specificity = 95%) with VL increase/decrease, respectively. QIFT-based viral clearance estimates showed similar values compared to PCR-based estimates. Variations in viral clearance rates were lower in treated compared to untreated patients. The study was limited by use of non-invasive, semi-quantitative nasopharyngeal samples. VL measurements below the limit of detection could not be quantified reliably.ConclusionsDuring follow-up, RIFT provides a first surrogate measure for influenza disease activity. A “switch” from positive to negative values may indicate a drop in viral load below a critical threshold, where rebound is no longer expected. QIFT may provide a useful tool for the monitoring of disease burden and viral clearance at the POC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care

Chen

Yousef²,

Duwe

et al. 2014

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, depending on workflow and resources within the laboratory, DFA testing as an adjunct to molecular test methods may provide an option for RSV testing in high-risk patients such as hematopoietic stem cell transplant patients (269). Prior to the broader utilization of easier-touse molecular diagnostic assays, DFA testing historically provided a more rapid response than lab-developed and batched molecular assays for RSV (270). As shown in Table 1, the sensitivity of DFA testing can be excellent in pediatric patient populations.…”

Section: Direct Fluorescent Antibody Testingmentioning

confidence: 99%

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment

2017

View full text Add to dashboard Cite

SUMMARY Respiratory syncytial virus (RSV) infection is a significant cause of hospitalization of children in North America and one of the leading causes of death of infants less than 1 year of age worldwide, second only to malaria. Despite its global impact on human health, there are relatively few therapeutic options available to prevent or treat RSV infection. Paradoxically, there is a very large volume of information that is constantly being refined on RSV replication, the mechanisms of RSV-induced pathology, and community transmission. Compounding the burden of acute RSV infections is the exacerbation of preexisting chronic airway diseases and the chronic sequelae of RSV infection. A mechanistic link is even starting to emerge between asthma and those who suffer severe RSV infection early in childhood. In this article, we discuss developments in the understanding of RSV replication, pathogenesis, diagnostics, and therapeutics. We attempt to reconcile the large body of information on RSV and why after many clinical trials there is still no efficacious RSV vaccine and few therapeutics.

show abstract

“…Direct virus detection is not suitable for the routine diagnosis of respiratory viral infection because the procedures require considerable skilled expertise and are often time-consuming. Serological approaches include nucleic acid sequence-based amplification (NASBA) [2], Restriction endonuclease analysis (REA) [3,4] and direct immunofluorescent assays [5]. Enzyme-linked immunosorbent assays (ELISAs) are commercially available [6,7], but they usually require long assay times and a labor-intensive sampling process.…”

Section: Introductionmentioning

confidence: 99%

Development of SPR biosensor for simultaneous detection of multiplex respiratory viruses

Shi

Sun

et al. 2015

BME

View full text Add to dashboard Cite

Abstract.A surface plasmon resonance (SPR)-based biosensor was developed for specific detection of nine common respiratory virus, including influenza A and influenza B, H1N1, respiratory syncytial virus (RSV), parainfluenza virus 1-3 (PIV1, 2, 3), adenovirus, and severe acute respiratory syndrome coronavirus (SARS). The SPR biosensor was developed by immobilizing nine respiratory virus-specific oligonucleotides in an SPR chip. To increase the biosensor sensitivity, biotin was used to label the PCR primer and further amplify the signal by introducing streptavidin after hybridization. Throat swab specimens representing nine common respiratory viruses were tested by the innovative SPR-based biosensor to evaluate the sensitivity, specificity and reproducibility of this method. Results suggest that this biosensor has the potential to simultaneously identify common respiratory viruses.

show abstract

Early detection of influenza A and B infection in infants and children using conventional and fluorescence-based rapid testing

Cited by 38 publications

References 33 publications

Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care

Quantitative Influenza Follow-Up Testing (QIFT)—A Novel Biomarker for the Monitoring of Disease Activity at the Point-of-Care

Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment

Development of SPR biosensor for simultaneous detection of multiplex respiratory viruses

Contact Info

Product

Resources

About